Antiviral Immunity Via RIG-I-mediated Recognition of RNA Bearing 5'-diphosphates
Authors
Affiliations
Mammalian cells possess mechanisms to detect and defend themselves from invading viruses. In the cytosol, the RIG-I-like receptors (RLRs), RIG-I (retinoic acid-inducible gene I; encoded by DDX58) and MDA5 (melanoma differentiation-associated gene 5; encoded by IFIH1) sense atypical RNAs associated with virus infection. Detection triggers a signalling cascade via the adaptor MAVS that culminates in the production of type I interferons (IFN-α and β; hereafter IFN), which are key antiviral cytokines. RIG-I and MDA5 are activated by distinct viral RNA structures and much evidence indicates that RIG-I responds to RNAs bearing a triphosphate (ppp) moiety in conjunction with a blunt-ended, base-paired region at the 5'-end (reviewed in refs 1, 2, 3). Here we show that RIG-I also mediates antiviral responses to RNAs bearing 5'-diphosphates (5'pp). Genomes from mammalian reoviruses with 5'pp termini, 5'pp-RNA isolated from yeast L-A virus, and base-paired 5'pp-RNAs made by in vitro transcription or chemical synthesis, all bind to RIG-I and serve as RIG-I agonists. Furthermore, a RIG-I-dependent response to 5'pp-RNA is essential for controlling reovirus infection in cultured cells and in mice. Thus, the minimal determinant for RIG-I recognition is a base-paired RNA with 5'pp. Such RNAs are found in some viruses but not in uninfected cells, indicating that recognition of 5'pp-RNA, like that of 5'ppp-RNA, acts as a powerful means of self/non-self discrimination by the innate immune system.
Innate Sensing of Viral Nucleic Acids and Their Use in Antiviral Vaccine Development.
Enya T, Ross S Vaccines (Basel). 2025; 13(2).
PMID: 40006739 PMC: 11860339. DOI: 10.3390/vaccines13020193.
ZUGC-RNA degradation generates immunosuppressor to evade immune responses in eukaryotes.
Gao S, Chen M, Wich D, Bloomer H, Qu Z, Guan H bioRxiv. 2025; .
PMID: 39974952 PMC: 11838226. DOI: 10.1101/2025.01.27.633273.
Li K, Yu X, Xu Y, Wang H, Liu Z, Wu C Nat Commun. 2025; 16(1):1629.
PMID: 39952937 PMC: 11828882. DOI: 10.1038/s41467-025-56407-7.
Cross-priming in cancer immunology and immunotherapy.
Luri-Rey C, Teijeira A, Wculek S, de Andrea C, Herrero C, Lopez-Janeiro A Nat Rev Cancer. 2025; .
PMID: 39881005 DOI: 10.1038/s41568-024-00785-5.
5' terminal nucleotide determines the immunogenicity of IVT RNAs.
Wolczyk M, Szymanski J, Trus I, Naz Z, Tame T, Bolembach A Nucleic Acids Res. 2024; 53(3).
PMID: 39704128 PMC: 11797061. DOI: 10.1093/nar/gkae1252.